Jubilant Pharmova Limited reported its financial results for the fourth quarter ended March 31, 2025, showcasing a sharp improvement in profitability and operating margins. The company’s consolidated net profit stood at Rs 151.3 crore in Q4 FY25, compared to a loss of Rs 61.8 crore in the same quarter last year.
The company’s total revenue from operations rose to Rs 1,928.8 crore in the March quarter, reflecting a year-on-year growth from Rs 1,758.6 crore reported in Q4 FY24. The increase was supported by robust performance across key segments.
Jubilant Pharmova’s EBITDA for the quarter rose to Rs 345 crore, up from Rs 271 crore in the same period last year. The EBITDA margin improved to 18% compared to 15.43% in Q4 FY24, indicating stronger operating efficiency.
For the full financial year 2025, the company posted a consolidated net profit of Rs 836.3 crore, significantly higher than Rs 72.7 crore in the previous year. Total income for the year reached Rs 7,291.3 crore, up from Rs 6,771.6 crore in FY24.
The management highlighted that the performance was driven by better operating leverage, improved cost management, and steady demand across its key therapeutic areas.
Disclaimer:
The information provided is for informational purposes only and should not be considered as financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a qualified financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
